Edition:
United Kingdom

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

119.07USD
22 Mar 2019
Change (% chg)

$-4.15 (-3.37%)
Prev Close
$123.22
Open
$122.51
Day's High
$123.07
Day's Low
$116.39
Volume
80,410
Avg. Vol
76,043
52-wk High
$131.69
52-wk Low
$53.29

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma Says Once-Weekly Transcon Growth Hormone Demonstrated Superiority On Primary Endpoint
Monday, 4 Mar 2019 

March 4 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA ANNOUNCES ONCE-WEEKLY TRANSCON™ GROWTH HORMONE DEMONSTRATED SUPERIORITY ON PRIMARY ENDPOINT COMPARED TO A DAILY GROWTH HORMONE IN PHASE 3 HEIGHT TRIAL FOR PEDIATRIC GROWTH HORMONE DEFICIENCY.ASCENDIS PHARMA A/S - RESULTS FROM TRIAL INDICATE THAT TRANSCON HGH WAS GENERALLY SAFE AND WELL-TOLERATED.ASCENDIS PHARMA A/S - ASCENDIS PLANS A CLINICAL DATABASE LOCK FOR TRANSCON HGH PHASE 3 PROGRAM IN Q3 OF 2019.ASCENDIS PHARMA - TO SUBMIT BIOLOGICS LICENSE APPLICATION (BLA) WITH FDA FOR TRANSCON HGH TO TREAT PEDIATRIC GHD IN FIRST HALF OF 2020.  Full Article

Ascendis Pharma Expects Results From Phase 3 Trial Of Transcon HGH In Q1
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S - TOP-LINE RESULTS FROM PHASE 3 HEIGHT TRIAL FOR TRANSCON HGH ARE EXPECTED IN Q1.ASCENDIS PHARMA A/S - TOP-LINE RESULTS FROM FLIGHT TRIAL (SWITCH) ARE EXPECTED IN Q2.ASCENDIS PHARMA A/S - TOP-LINE RESULTS FROM A PHASE 2 TRIAL FOR TRANSCON PTH ARE EXPECTED IN Q4.ASCENDIS PHARMA A/S - A PHASE 2 TRIAL OF TRANSCON CNP IN CHILDREN WITH ACHONDROPLASIA IS EXPECTED TO BE INITIATED IN Q3.ASCENDIS PHARMA A/S - HAS ESTABLISHED ONCOLOGY AS ITS SECOND INDEPENDENT THERAPEUTIC AREA.  Full Article

Ascendis Pharma Reports Third Quarter 2018 Financial Results
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Ascendis Pharma A/S ::REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE EUR 0.81.Q3 EARNINGS PER SHARE ESTIMATE EUR -1.06 -- REFINITIV IBES DATA.ON TRACK TO REPORT TOP-LINE RESULTS IN Q1 OF 2019 FOR PHASE 3 HEIGHT TRIAL.  Full Article

Ascendis Pharma Announces Positive Preliminary Phase 1 Data For Transcon CNP
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES POSITIVE PRELIMINARY PHASE 1 DATA FOR TRANSCON CNP.ASCENDIS PHARMA A/S - COMPANY PLANS TO INITIATE A PHASE 2 PROGRAM OF TRANSCON CNP IN PEDIATRIC SUBJECTS WITH ACHONDROPLASIA IN MID-2019.ASCENDIS PHARMA A/S - TRANSCON CNP PHASE 1 RESULTS REINFORCE PRECLINICAL DATA AND SUPPORT TARGET PRODUCT PROFILE.ASCENDIS PHARMA A/S - TRANSCON CNP DELIVERED CONTINUOUS EXPOSURE OF CNP AT TARGET LEVELS FOR SEVEN DAYS WITH A SINGLE SUBCUTANEOUS ADMINISTRATION.  Full Article

Ascendis Pharma Q2 Loss Per Share EUR 0.55
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Ascendis Pharma A/S ::REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE EUR 0.55.Q2 EARNINGS PER SHARE VIEW EUR -0.90 -- THOMSON REUTERS I/B/E/S.  Full Article

Ascendis Pharma Files For Potential Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Wednesday, 30 May 2018 

May 30 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article